HUMAN TRIAL RESULTS SHOW EXCELLENT SAFETY DATA, FROM GEOVAX’S DNA/MVA AIDS VACCINES

GeoVax Labs, Inc. an Atlanta-based biotechnology association, currently reported successful early formula from dual ongoing AIDS impediment Phase we tellurian vaccine trials. Formula from the initial low-dose hearing prove the great reserve form as great as certain defence responses in tellurian volunteers reception 1/10th sip of GeoVax’s AIDS vaccine. Formula from the second incomparable full-dose hearing additionally prove the great reserve form in participants.

Tags: ,

Related posts

Leave a Comment

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.